# This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

> **NCT03351244** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 264 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** BI 409306
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03351244
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-07
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-31
- **Target enrollment:** 264 (ACTUAL)
- **Why stopped:** disruption due to COVID-19
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03351244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03351244, "This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03351244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*